aztreonam has been researched along with Chronic Kidney Failure in 8 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics of aztreonam and vancomycin were studied in six adult patients who developed peritonitis during Continuous Ambulatory Peritoneal Dialysis." | 7.68 | Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis. ( Altmann, P; Brown, J; Cunningham, J; Marsh, F; Shaw, E, 1990) |
| " administration of aztreonam (A) and cefuroxime (C), 10 adult CAPD patients (pts) with peritonitis were trained to start the following treatment procedure: a) sterile collection of dialysate effluent for cultures; b) 4 rapid in-and-out exchanges with antibiotic free dialysate; c) addition of 2 g C and 2 g A to a 2-L exchange for 6-h dwell time (the same dosage was repeated once a day in the overnight exchange); d) routine CAPD exchanges." | 5.28 | Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). ( Conte, G; Fuiano, G; Nani, E; Sepe, V; Viscione, M, 1989) |
| "The pharmacokinetics of aztreonam and vancomycin were studied in six adult patients who developed peritonitis during Continuous Ambulatory Peritoneal Dialysis." | 3.68 | Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis. ( Altmann, P; Brown, J; Cunningham, J; Marsh, F; Shaw, E, 1990) |
| "CLurea by CAPD was 6." | 2.65 | Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. ( Bolton, ND; Bolton, WK; Gerig, JS; Scheld, WM; Swabb, EA, 1984) |
| "Aztreonam appears to be a potentially useful antibiotic for CAPD peritonitis." | 1.28 | Pharmacokinetics of aztreonam administered i.p. in continuous ambulatory peritoneal dialysis (CAPD) patients. ( Alexiou, P; Balaskas, E; Dombros, N; Nikolaidis, P; Tourkantonis, A, 1989) |
| " administration of aztreonam (A) and cefuroxime (C), 10 adult CAPD patients (pts) with peritonitis were trained to start the following treatment procedure: a) sterile collection of dialysate effluent for cultures; b) 4 rapid in-and-out exchanges with antibiotic free dialysate; c) addition of 2 g C and 2 g A to a 2-L exchange for 6-h dwell time (the same dosage was repeated once a day in the overnight exchange); d) routine CAPD exchanges." | 1.28 | Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). ( Conte, G; Fuiano, G; Nani, E; Sepe, V; Viscione, M, 1989) |
| " The half-life of elimination (t 1/2/beta) increased significantly (P less than 0." | 1.28 | Single-dose pharmacokinetics of aztreonam in healthy volunteers and renal failure patients. ( Abd el Bary, M; el Guinaidy, MA; Nawishy, S; Sabbour, MS, 1989) |
| " Because of the large variation in the degree of renal insufficiency, calculations of the mean values for the pharmacokinetic parameters in the patient group were not generally justified with the exception of the volume of distribution (Vdss = 14." | 1.27 | Pharmacokinetics and dose recommendations of carumonam in renal failure. ( Höffler, D; Koeppe, P; Strobel, K, 1987) |
| " The elimination half-life of carumonam increased with decreasing creatinine clearance (CLCR) from 1." | 1.27 | Pharmacokinetics of carumonam in patients with renal insufficiency. ( Dubach, UC; Egger, HJ; Frey, FJ; Horber, F; Probst, PJ; Stoeckel, K; Weidekamm, E, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (75.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gross, AE | 1 |
| Xu, H | 1 |
| Zhou, D | 1 |
| Al-Huniti, N | 1 |
| Gerig, JS | 1 |
| Bolton, ND | 1 |
| Swabb, EA | 1 |
| Scheld, WM | 1 |
| Bolton, WK | 1 |
| Brown, J | 1 |
| Altmann, P | 1 |
| Cunningham, J | 1 |
| Shaw, E | 1 |
| Marsh, F | 1 |
| Nikolaidis, P | 1 |
| Dombros, N | 1 |
| Alexiou, P | 1 |
| Balaskas, E | 1 |
| Tourkantonis, A | 1 |
| Fuiano, G | 1 |
| Sepe, V | 1 |
| Viscione, M | 1 |
| Nani, E | 1 |
| Conte, G | 1 |
| el Guinaidy, MA | 1 |
| Nawishy, S | 1 |
| Abd el Bary, M | 1 |
| Sabbour, MS | 1 |
| Koeppe, P | 1 |
| Höffler, D | 1 |
| Strobel, K | 1 |
| Horber, F | 1 |
| Egger, HJ | 1 |
| Weidekamm, E | 1 |
| Dubach, UC | 1 |
| Frey, FJ | 1 |
| Probst, PJ | 1 |
| Stoeckel, K | 1 |
1 trial available for aztreonam and Chronic Kidney Failure
| Article | Year |
|---|---|
Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Biological Availability; Female; Humans; Kidney Failure, Ch | 1984 |
7 other studies available for aztreonam and Chronic Kidney Failure
| Article | Year |
|---|---|
Simplified Aztreonam Dosing in Patients with End-Stage Renal Disease: Results of a Monte Carlo Simulation.
Topics: Anti-Bacterial Agents; Aztreonam; Humans; Kidney Failure, Chronic; Male; Monte Carlo Method; Probabi | 2018 |
Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis.
Topics: Aztreonam; Humans; Injections, Intraperitoneal; Kidney Failure, Chronic; Middle Aged; Peritoneal Dia | 1990 |
Pharmacokinetics of aztreonam administered i.p. in continuous ambulatory peritoneal dialysis (CAPD) patients.
Topics: Adult; Aztreonam; Biological Availability; Female; Half-Life; Humans; Infusions, Parenteral; Kidney | 1989 |
Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD).
Topics: Aztreonam; Cefuroxime; Drug Administration Schedule; Drug Therapy, Combination; Evaluation Studies a | 1989 |
Single-dose pharmacokinetics of aztreonam in healthy volunteers and renal failure patients.
Topics: Adult; Aztreonam; Creatinine; Drug Administration Schedule; Humans; Injections, Intravenous; Kidney | 1989 |
Pharmacokinetics and dose recommendations of carumonam in renal failure.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Humans; Kidney Failure, Chronic; Kinetics; Lactams; M | 1987 |
Pharmacokinetics of carumonam in patients with renal insufficiency.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Chromatography, High Pressure Liquid; Creatinine; Female; H | 1986 |